We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Protagonist Therapeutics Inc | NASDAQ:PTGX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 26.09 | 26.00 | 28.00 | 0 | 09:56:31 |
From May 2021 to May 2024
By Matt Grossman
Protagonist Therapeutics Inc. said Monday that the U.S. Food and Drug Administration has lifted its clinical hold on rusfertide, allowing trials using the drug to resume.
The hold had been put in place after a finding that mice used in a study had developed benign and malignant skin tumors.
"No other unexpected safety signals surfaced" from the review that followed, Protagonist said.
A Phase 3 study for the drug's use in treating polycthemia vera, a type of blood cancer, could begin in next year's first quarter, Protagonist said.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
October 11, 2021 07:37 ET (11:37 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Protagonist Therapeutics Chart |
1 Month Protagonist Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
